Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD

Hazel H. Szeto, Shaoyi Liu, Yi Soong, Surya V. Seshan, Leona Cohen-Gould, Viacheslav Manichev, Leonard C Feldman, Torgny Gustafsson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The innate immune systemhas been implicated in both AKI and CKD. Damagedmitochondria release danger molecules, such as reactive oxygen species, DNA, and cardiolipin, which can cause NLRP3 inflammasome activation and upregulation of IL-18 and IL-1β. It is not known if mitochondrial damage persists long after ischemia to sustain chronic inflammasome activation.We conducted a 9-month study in Sprague-Dawley rats after 45 minutes of bilateral renal ischemia. We detected glomerular and peritubular capillary rarefaction, macrophage infiltration, and fibrosis at 1 month. Transmission electron microscopy revealed mitochondrial degeneration, mitophagy, and deformed foot processes in podocytes. These changes progressed over the study period, with a persistent increase in renal cortical expression of IL-18, IL-1β, and TGF-β, despite a gradual decline in TNF-α expression and macrophage infiltration. Treatment with a mitoprotective agent (SS-31; elamipretide) for 6 weeks, starting 1month after ischemia, preservedmitochondrial integrity, ameliorated expression levels of all inflammatory markers, restored glomerular capillaries and podocyte structure, and arrested glomerulosclerosis and interstitial fibrosis. Further, heliumion microscopy vividly demonstrated the restoration of podocyte structure by SS-31. The protection by SS-31 was sustained for ≥6 months after treatment ended,with normalization of IL-18 and IL-1β expression. These results support a role for mitochondrial damage in inflammasome activation and CKD and suggest mitochondrial protection as a novel therapeutic approach that can arrest the progression of CKD.Notably, SS-31 is effective when given long after AKI and provides persistent protection after termination of drug treatment.

Original languageEnglish
Pages (from-to)1437-1449
Number of pages13
JournalJournal of the American Society of Nephrology
Volume28
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Inflammasomes
Podocytes
Interleukin-18
Interleukin-1
Mitochondria
Up-Regulation
Ischemia
Fibrosis
Mitochondrial Degradation
Macrophages
Kidney
Cardiolipins
Transmission Electron Microscopy
Sprague Dawley Rats
Foot
Microscopy
Reactive Oxygen Species
DNA
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD. / Szeto, Hazel H.; Liu, Shaoyi; Soong, Yi; Seshan, Surya V.; Cohen-Gould, Leona; Manichev, Viacheslav; Feldman, Leonard C; Gustafsson, Torgny.

In: Journal of the American Society of Nephrology, Vol. 28, No. 5, 01.05.2017, p. 1437-1449.

Research output: Contribution to journalArticle

Szeto, Hazel H. ; Liu, Shaoyi ; Soong, Yi ; Seshan, Surya V. ; Cohen-Gould, Leona ; Manichev, Viacheslav ; Feldman, Leonard C ; Gustafsson, Torgny. / Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD. In: Journal of the American Society of Nephrology. 2017 ; Vol. 28, No. 5. pp. 1437-1449.
@article{06df5cd4f6174f2cbd03b4ec0122f923,
title = "Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD",
abstract = "The innate immune systemhas been implicated in both AKI and CKD. Damagedmitochondria release danger molecules, such as reactive oxygen species, DNA, and cardiolipin, which can cause NLRP3 inflammasome activation and upregulation of IL-18 and IL-1β. It is not known if mitochondrial damage persists long after ischemia to sustain chronic inflammasome activation.We conducted a 9-month study in Sprague-Dawley rats after 45 minutes of bilateral renal ischemia. We detected glomerular and peritubular capillary rarefaction, macrophage infiltration, and fibrosis at 1 month. Transmission electron microscopy revealed mitochondrial degeneration, mitophagy, and deformed foot processes in podocytes. These changes progressed over the study period, with a persistent increase in renal cortical expression of IL-18, IL-1β, and TGF-β, despite a gradual decline in TNF-α expression and macrophage infiltration. Treatment with a mitoprotective agent (SS-31; elamipretide) for 6 weeks, starting 1month after ischemia, preservedmitochondrial integrity, ameliorated expression levels of all inflammatory markers, restored glomerular capillaries and podocyte structure, and arrested glomerulosclerosis and interstitial fibrosis. Further, heliumion microscopy vividly demonstrated the restoration of podocyte structure by SS-31. The protection by SS-31 was sustained for ≥6 months after treatment ended,with normalization of IL-18 and IL-1β expression. These results support a role for mitochondrial damage in inflammasome activation and CKD and suggest mitochondrial protection as a novel therapeutic approach that can arrest the progression of CKD.Notably, SS-31 is effective when given long after AKI and provides persistent protection after termination of drug treatment.",
author = "Szeto, {Hazel H.} and Shaoyi Liu and Yi Soong and Seshan, {Surya V.} and Leona Cohen-Gould and Viacheslav Manichev and Feldman, {Leonard C} and Torgny Gustafsson",
year = "2017",
month = "5",
day = "1",
doi = "10.1681/ASN.2016070761",
language = "English",
volume = "28",
pages = "1437--1449",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1b and IL-18 and arrests CKD

AU - Szeto, Hazel H.

AU - Liu, Shaoyi

AU - Soong, Yi

AU - Seshan, Surya V.

AU - Cohen-Gould, Leona

AU - Manichev, Viacheslav

AU - Feldman, Leonard C

AU - Gustafsson, Torgny

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The innate immune systemhas been implicated in both AKI and CKD. Damagedmitochondria release danger molecules, such as reactive oxygen species, DNA, and cardiolipin, which can cause NLRP3 inflammasome activation and upregulation of IL-18 and IL-1β. It is not known if mitochondrial damage persists long after ischemia to sustain chronic inflammasome activation.We conducted a 9-month study in Sprague-Dawley rats after 45 minutes of bilateral renal ischemia. We detected glomerular and peritubular capillary rarefaction, macrophage infiltration, and fibrosis at 1 month. Transmission electron microscopy revealed mitochondrial degeneration, mitophagy, and deformed foot processes in podocytes. These changes progressed over the study period, with a persistent increase in renal cortical expression of IL-18, IL-1β, and TGF-β, despite a gradual decline in TNF-α expression and macrophage infiltration. Treatment with a mitoprotective agent (SS-31; elamipretide) for 6 weeks, starting 1month after ischemia, preservedmitochondrial integrity, ameliorated expression levels of all inflammatory markers, restored glomerular capillaries and podocyte structure, and arrested glomerulosclerosis and interstitial fibrosis. Further, heliumion microscopy vividly demonstrated the restoration of podocyte structure by SS-31. The protection by SS-31 was sustained for ≥6 months after treatment ended,with normalization of IL-18 and IL-1β expression. These results support a role for mitochondrial damage in inflammasome activation and CKD and suggest mitochondrial protection as a novel therapeutic approach that can arrest the progression of CKD.Notably, SS-31 is effective when given long after AKI and provides persistent protection after termination of drug treatment.

AB - The innate immune systemhas been implicated in both AKI and CKD. Damagedmitochondria release danger molecules, such as reactive oxygen species, DNA, and cardiolipin, which can cause NLRP3 inflammasome activation and upregulation of IL-18 and IL-1β. It is not known if mitochondrial damage persists long after ischemia to sustain chronic inflammasome activation.We conducted a 9-month study in Sprague-Dawley rats after 45 minutes of bilateral renal ischemia. We detected glomerular and peritubular capillary rarefaction, macrophage infiltration, and fibrosis at 1 month. Transmission electron microscopy revealed mitochondrial degeneration, mitophagy, and deformed foot processes in podocytes. These changes progressed over the study period, with a persistent increase in renal cortical expression of IL-18, IL-1β, and TGF-β, despite a gradual decline in TNF-α expression and macrophage infiltration. Treatment with a mitoprotective agent (SS-31; elamipretide) for 6 weeks, starting 1month after ischemia, preservedmitochondrial integrity, ameliorated expression levels of all inflammatory markers, restored glomerular capillaries and podocyte structure, and arrested glomerulosclerosis and interstitial fibrosis. Further, heliumion microscopy vividly demonstrated the restoration of podocyte structure by SS-31. The protection by SS-31 was sustained for ≥6 months after treatment ended,with normalization of IL-18 and IL-1β expression. These results support a role for mitochondrial damage in inflammasome activation and CKD and suggest mitochondrial protection as a novel therapeutic approach that can arrest the progression of CKD.Notably, SS-31 is effective when given long after AKI and provides persistent protection after termination of drug treatment.

UR - http://www.scopus.com/inward/record.url?scp=85021851167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021851167&partnerID=8YFLogxK

U2 - 10.1681/ASN.2016070761

DO - 10.1681/ASN.2016070761

M3 - Article

C2 - 27881606

AN - SCOPUS:85021851167

VL - 28

SP - 1437

EP - 1449

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -